Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2022. Available from: https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf. Accessed May, 2023.
   Google Scholar
• Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8(2):429–440. doi:10.1016/j.jaip.2019.11.008
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol. 2003;112(2):252–262. doi:10.1067/mai.2003.1595
   PubMed Web of Science ®Google Scholar
• Oppenheimer J, Hoyte FCL, Phipatanakul W, Silver J, Howarth P, Lugogo NL. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol. 2022;129(2):169–180. doi:10.1016/j.anai.2022.02.021
   PubMed Web of Science ®Google Scholar
• Chen M, Shepard K 2nd, Yang M, et al. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021;51(4):546–555. doi:10.1111/cea.13790
   PubMed Web of Science ®Google Scholar
• EMA. Nucala: EPAR - product information; 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf. Accessed April 13, 2023.
   Google Scholar
• FDA. NUCALA prescribing information; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761122s008,125526s019lbl.pdf. Accessed April 13, 2023.
   Google Scholar
• Abdala-Valencia H, Coden ME, Chiarella SE, et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. J Leukoc Biol. 2018;104(1):95–108. doi:10.1002/JLB.1MR1117-442RR
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Suda T, Ohta S, Tominaga K, Miura Y, Kasahara T. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood. 1991;78(10):2542–2547. doi:10.1182/blood.V78.10.2542.2542
   PubMed Web of Science ®Google Scholar
• Pavord ID, Menzies-Gow A, Buhl R, et al. Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine. J Allergy Clin Immunol Pract. 2021;9(3):1121–1132.e1127. doi:10.1016/j.jaip.2020.08.039
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Khurana S, Brusselle GG, Bel EH, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX Study. Clin Ther. 2019;41(10):2041–2056.e2045. doi:10.1016/j.clinthera.2019.07.007
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Lemiere C, Taillé C, Lee JK, et al. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. Respir Res. 2021;22(1):184. doi:10.1186/s12931-021-01767-z
   PubMed Web of Science ®Google Scholar
• Prazma CM, Idzko M, Douglass JA, et al. Response to mepolizumab treatment in patients with severe eosinophilic asthma and atopic phenotypes. J Asthma Allergy. 2021;14:675–683. doi:10.2147/JAA.S298559
   PubMed Web of Science ®Google Scholar
• Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151. doi:10.1183/13993003.00151-2020
   PubMed Web of Science ®Google Scholar
• Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10(10):2646–2656. doi:10.1016/j.jaip.2022.05.042
   PubMed Web of Science ®Google Scholar
• Domingo Ribas C, Carrillo Díaz T, Blanco Aparicio M, Martínez Moragón E, Banas Conejero D, Sánchez Herrero MG. REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES Study. Drugs. 2021;81(15):1763–1774. doi:10.1007/s40265-021-01597-9
   PubMed Web of Science ®Google Scholar
• Taillé C, Chanez P, Devouassoux G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Europ Resp J. 2020;55(6):1902345. doi:10.1183/13993003.02345-2019
   PubMed Web of Science ®Google Scholar
• Ortega H, Chupp G, Bardin P, et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J. 2014;44(1):239–241. doi:10.1183/09031936.00220413
   PubMed Web of Science ®Google Scholar
• Humbert M, Albers FC, Bratton DJ, et al. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respir Med. 2019;154:69–75. doi:10.1016/j.rmed.2019.06.004
   PubMed Web of Science ®Google Scholar
• Albers FC, Hozawa S, Bratton DJ, et al. Update: mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use. Allergy. 2020;75(4):942–946. doi:10.1111/all.14048
   PubMed Web of Science ®Google Scholar
• Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019;74(9):1716–1726. doi:10.1111/all.13850
   PubMed Web of Science ®Google Scholar
• Liu MC, Chipps B, Munoz X, et al. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respir Res. 2021;22(1):144. doi:10.1186/s12931-021-01733-9
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33(34):e213. doi:10.3346/jkms.2018.33.e213
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Camiciottoli G, et al. Mepolizumab effectiveness and allergic status in real life. Int Arch Allergy Immunol. 2021;182(4):311–318. doi:10.1159/000511147
   PubMed Web of Science ®Google Scholar
• Casale T, Molfino NA, Silver J, et al. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Ann Allergy Asthma Immunol. 2021;127(3):354–362.e352. doi:10.1016/j.anai.2021.05.021
   PubMed Web of Science ®Google Scholar
• Optum. Retrospective database analysis; 2013. Available from: https://www.optum.com/content/dam/optum/resources/productSheets/Retrospective-Database-Analysis.pdf. Accessed April 24, 2023.
   Google Scholar
• Lugogo NL, Bogart M, Corbridge T, Packnett ER, Wu J, Hahn B. Impact of mepolizumab in patients with high-burden severe asthma within a managed care population. J Asthma. 2023;60(4):811–823. doi:10.1080/02770903.2022.2102036
   PubMed Web of Science ®Google Scholar
• Ortega H, Hahn B, Bogart M, et al. Impact of mepolizumab on exacerbations in severe asthma: results from a U.S. insurance claims data base. Allergy Asthma Proc. 2020;41(5):341–347. doi:10.2500/aap.2020.41.200043
   PubMed Web of Science ®Google Scholar
• Sethi S, Bogart M, Corbridge T, Cyhaniuk A, Hahn B. Impact of mepolizumab on exacerbations in the US medicare population. J Allergy Clin Immunol Pract. 2023;11(2):546–554.e542. doi:10.1016/j.jaip.2022.10.021
   PubMed Web of Science ®Google Scholar
• Silver J, Bogart M, Packnett E, Wu J, McMorrow D, Hahn B. Real-world reductions in oral corticosteroid use in the USA following mepolizumab therapy for severe asthma. J Asthma Allergy. 2020;13:689–699. doi:10.2147/JAA.S275944
   PubMed Web of Science ®Google Scholar
• Silver J, Molfino N, Bogart M, et al. Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis. Clin Ther. 2021;43(12):2064–2073. doi:10.1016/j.clinthera.2021.10.010
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma. Adv Ther. 2020;37(2):718–729. doi:10.1007/s12325-019-01191-2
   PubMed Web of Science ®Google Scholar
• Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140(6):1509–1518. doi:10.1016/j.jaci.2017.10.005
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar